The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Principles of nanoparticle design for overcoming biological barriers to drug delivery
Open accessAbstract
Biological barriers to drug transport prevent successful accumulation of nanotherapeutics specifically at diseased sites, limiting efficacious responses in disease processes ranging from cancer to inflammation. Although substantial research efforts have aimed to incorporate multiple functionalities and moieties within the overall nanoparticle design, many of these strategies fail to adequately address these barriers. Obstacles, such as nonspecific distribution and inadequate accumulation of therapeutics, remain formidable challenges to drug developers. A reimagining of conventional nanoparticles is needed to successfully negotiate these impediments to drug delivery. Site-specific delivery of therapeutics will remain a distant reality unless nanocarrier design takes into account the majority, if not all, of the biological barriers that a particle encounters upon intravenous administration. By successively addressing each of these barriers, innovative design features can be rationally incorporated that will create a new generation of nanotherapeutics, realizing a paradigmatic shift in nanoparticle-based drug delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nanoparticles will accumulate in the liver if their sizes are comparable to the size of vascular fenestration of the liver (50–100 nm) or end up in the spleen if their sizes are close to interendothelial cell slits of the spleen (100–200 nm).217”
From The Pursuit of Shortwave Infrared-Emitting Nanoparticles with Bright Fluorescence through Molecular Design and Excited-State Engineering of Molecular Aggregates (2022) · cites this paper as [217]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crossing the BBB with various nanoparticles, such as liposomes, cationic polymers, inorganic nanoparticles, and nanocapsules, has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among a number of approaches, crossing the BBB with various nanoparticles has shown promise in delivery of various cargos into the CNS, but complicated modifications are always needed to ensure that the particles produced are BBB-permeable (15, 18, 19).”
From Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredIn the citing paper
“To demonstrate the colloidal stability of the NP-Pep, we determined the zeta potential (ζ-potential) of the NP-Pep suspended in 0.1× PBS buffer (pH 7.4) to be ~−38 mV, which has been previously shown to be both ideal for serum protein applications and sufficient for electrostatic repulsive forces to dominate over the van der Waals force, such that agglomeration is suppressed (Supplementary Fig. 11”
From Nanoproteomics enables proteoform-resolved analysis of low-abundance proteins in human serum (2020) · cites this paper as [45]
In the citing paper
“For example, nanomaterial properties such as size, geometry, material composition and surface chemistry can greatly influence the interactions of the nanomaterials with biological systems49,50.”
From How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation (2018) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Renal clearance of quantum dots
Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,029
Nanoengineered Templated Polymer Particles: Navigating the Biological Realm
Cui, J., Richardson, J. J., Björnmalm, M., Faria, M., & Caruso, F. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.6b00088 · Cited by 130
Atomic Force Microscopy in Characterizing Cell Mechanics for Biomedical Applications: A Review
Li, M., Dang, D., Liu, L., Xi, N., & Wang, Y. (2017) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2017.2714462 · Cited by 131
“pharmacokinetic limitations associated with conventional drug formulations [98].”
BackgroundRecent advances and prospects in gemcitabine drug delivery systems
Paroha, S., Verma, J., Dubey, R. D., Dewangan, R. P., Molugulu, N., Bapat, R. A., Sahoo, P. K., & Kesharwani, P. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.120043 · Cited by 130
Kim-1 Targeted Extracellular Vesicles: A New Therapeutic Platform for RNAi to Treat AKI
Tang, T., Wang, B., Li, Z., Wen, Y., Feng, S., Wu, M., Liu, D., Cao, J.-Y., Yin, Q., Yin, D., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020111561 · Cited by 129
Endocytosis of abiotic nanomaterials and nanobiovectors: Inhibition of membrane trafficking
Makvandi, P., Chen, M., Sartorius, R., Zarrabi, A., Ashrafizadeh, M., Moghaddam, F. D., Ma, J., Mattoli, V., & Tay, F. R. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101279 · Cited by 131
“The low pH and enzyme-rich intracellular environment as well as the presence of lysosomes may result in degradation or non-specific distribution of nanomaterials [7,8].”
BackgroundTowards principled design of cancer nanomedicine to accelerate clinical translation
Souri, M., Soltani, M., Moradi Kashkooli, F., Kiani Shahvandi, M., Chiani, M., Shariati, F. S., Mehrabi, M. R., & Munn, L. L. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100208 · Cited by 159
“Many foreign substances, including therapeutic agents, are expelled from the cell by MDR pumps, thus reducing therapeutic impact [49].”
BackgroundInfluentialTan, T., Hu, H., Wang, H., Li, J., Wang, Z., Wang, J., Wang, S., Zhang, Z., & Li, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-11235-4 · Cited by 130
Yang, K., Liu, Y., Wang, Y., Ren, Q., Guo, H., Matson, J. B., Chen, X. S., & Nie, Z. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119460 · Cited by 128
PGMD/curcumin nanoparticles for the treatment of breast cancer
Kumari, M. R., Sharma, N., Manchanda, R., Gupta, N., Syed, A., Bahkali, A. H., & Nimesh, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-81701-x · Cited by 128
Understanding nanoparticle-liver interactions in nanomedicine
He, Y., Wang, Y., Wang, L., Jiang, W., & Wilhelm, S. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2375400 · Cited by 145
“The enhanced boundary dynamics of these disc-shaped particles in blood flow strengthen their binding to endothelial cells and the possibility of extravasation through the discontinuous endothelial layer in tumor vessels [26].”
InfluentialHu, X., Sun, J., Li, F., Li, R., Wu, J., He, J., Wang, N., Liu, J., Wang, S., Zhou, F., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b04741 · Cited by 129
Nanoparticles That Deliver RNA to Bone Marrow Identified by in Vivo Directed Evolution
Sago, C. D., Lokugamage, M. P., Islam, F. Z., Krupczak, B. R., Sato, M., & Dahlman, J. E. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08976 · Cited by 132
Microfluidic Generation of Nanomaterials for Biomedical Applications
Zhao, X., Bian, F., Sun, L., Cai, L., Li, L., & Zhao, Y. (2019) · Small · doi:10.1002/smll.201901943 · Cited by 126
Bioresponsive immune-booster-based prodrug nanogel for cancer immunotherapy
Ma, X., Yang, S., Zhang, T., Wang, S., Yang, Q., Xiao, Y., Shi, X., Xue, P., Kang, Y., Liu, G., et al. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.016 · Cited by 125
Precise Subcellular Organelle Targeting for Boosting Endogenous‐Stimuli‐Mediated Tumor Therapy
Zhen, W., An, S., Wang, S., Hu, W., Li, Y., Jiang, X., & Li, J. (2021) · Advanced Materials · doi:10.1002/adma.202101572 · Cited by 127
Smart transformable nanoparticles for enhanced tumor theranostics
Chen, J., Jiang, Z., Zhang, Y. S., Ding, J., & Chen, X. (2021) · Applied Physics Reviews · doi:10.1063/5.0061530 · Cited by 127
Mechanisms of transport of polymeric and lipidic nanoparticles across the intestinal barrier
Beloqui, A., Rieux, A. D., & Véronique Préat, A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.014 · Cited by 131
Polymer-based nanoparticles for protein delivery: design, strategies and applications
Zhao, H., Lin, Z. Y., Yildirimer, L., Dhinakar, A., Zhao, X., & Wu, J. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb00308g · Cited by 128
Chen, Q., Liu, L., Lü, Y., Chen, X., Zhang, Y., Zhou, W., Guo, Q., Li, C., Zhang, Y., Zhang, Y. X., et al. (2019) · Advanced Science · doi:10.1002/advs.201802134 · Cited by 125
Development of nanoparticle-delivery systems for antiviral agents: A review
Delshadi, R., Bahrami, A., McClements, D. J., Moore, M. D., & Williams, L. L. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.017 · Cited by 132
“For instance, it has been reported that under normal flow conditions within blood vessels, the tendency for particles to stick to the endothelial cell surfaces increases as their size increases, which may be important for the uptake of antivirals into the body [20].”
The role and application of small extracellular vesicles in gastric cancer
Wu, H., Fu, M., Liu, J., Chong, W., Fang, Z., Du, F., Liu, Y., Shang, L., & Li, L. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01365-z · Cited by 125
“Efficient delivery and targeting of therapeutic cargo need be achieved to combat tumours, and sEVs can be used as drug delivery vehicles due to their unique physiochemical characteristics, high bioavailability and low nontargeted cytotoxicity [172].”
BackgroundMild Innate Immune Activation Overrides Efficient Nanoparticle‐Mediated RNA Delivery
Lokugamage, M. P., Gan, Z., Zurla, C., Levin, J., Islam, F. Z., Kalathoor, S., Sato, M., Sago, C. D., Santangelo, P. J., & Dahlman, J. E. (2020) · Advanced Materials · doi:10.1002/adma.201904905 · Cited by 126
Li, P., Liu, L., Lu, Q., Yang, S., Yang, L., Cheng, Y. S., Wang, Y., Wang, S., Song, Y., Tan, F., et al. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b18924 · Cited by 125
Li, Y., Dang, J., Liang, Q., & Yin, L. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00216 · Cited by 126
Drug Delivery with Designed Peptide Assemblies
Sis, M. J., & Webber, M. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.08.003 · Cited by 125
Xu, L., Xu, M., Wang, R., Yin, Y., Lynch, I., & Liu, S. (2020) · Small · doi:10.1002/smll.202003691 · Cited by 132
Youssef, Z., Vanderesse, R., Colombeau, L., Baros, F., Roques‐Carmes, T., Frochot, C., Wahab, H. A., Toufaily, J., Hamieh, T., Acherar, S., et al. (2017) · Cancer Nanotechnology · doi:10.1186/s12645-017-0032-2 · Cited by 124
Recent advances in nanotherapeutic strategies for spinal cord injury repair
Song, Y. H., Agrawal, N. K., Griffin, J. M., & Schmidt, C. E. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.011 · Cited by 124
Recent trends in cell membrane-cloaked nanoparticles for therapeutic applications
Choi, B., Park, W., Park, S.-B., Rhim, W.-K., & Han, D. K. (2019) · Methods · doi:10.1016/j.ymeth.2019.12.004 · Cited by 123
Qin, Y., Feng, Y., Ma, Y., He, X., Li, W., & Zhang, Y. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c05154 · Cited by 124
A quantitative view on multivalent nanomedicine targeting
Woythe, L., Tito, N. B., & Albertazzi, L. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.11.010 · Cited by 130
Inorganic Nanoparticles Applied for Active Targeted Photodynamic Therapy of Breast Cancer
Montaseri, H., Kruger, C. A., & Abrahamse, H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030296 · Cited by 124
Pan, Y., Tang, W., Fan, W., Zhang, J., & Chen, X. S. (2022) · Chemical Society Reviews · doi:10.1039/d1cs01145f · Cited by 127
Gao, X. J., Ciura, K., Ma, Y., Mikołajczyk, A., Jagiełło, K., Wan, Y., Gao, Y., Zheng, J., Zhong, S., Puzyn, T., et al. (2024) · Advanced Materials · doi:10.1002/adma.202407793 · Cited by 127
Moayedi, S., Xia, W., Lundergan, L., Yuan, H., & Xu, J. (2024) · Langmuir · doi:10.1021/acs.langmuir.4c02664 · Cited by 128
Li, D., Ma, Y., Du, J., Tao, W., Du, X., Yang, X., & Wang, J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b05396 · Cited by 123
Wang, D., Yu, C., Xu, L., Shi, L., Tong, G., Wu, J., Liu, H. S., Yan, D., & Zhu, X. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b04556 · Cited by 123
Diffusiophoretic separation of colloids in microfluidic flows
Shin, S. (2020) · Physics of Fluids · doi:10.1063/5.0023415 · Cited by 123
Che, J., Najer, A., Blakney, A. K., McKay, P. F., Bellahcene, M., Winter, C. W., Sintou, A., Tang, J., Keane, T. J., Schneider, M. D., et al. (2020) · Advanced Materials · doi:10.1002/adma.202003598 · Cited by 123
Mamidi, N., & Delgadillo, R. M. V. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111819 · Cited by 123
Yue, Y., Li, F.-F., Li, Y., Wang, Y., Guo, X., Cheng, Z.-X., Li, N., Ma, X., Nie, G., & Zhao, X. (2021) · ACS Nano · doi:10.1021/acsnano.1c05618 · Cited by 109
Nanotechnology for Targeted Detection and Removal of Bacteria: Opportunities and Challenges
Hajipour, M. J., Saei, A. A., Walker, E. D., Conley, B., Omidi, Y., Lee, K., & Mahmoudi, M. (2021) · Advanced Science · doi:10.1002/advs.202100556 · Cited by 122
Transvascular transport of nanocarriers for tumor delivery
Li, X., Hu, Y. M., Zhang, X., Shi, X., Parak, W. J., & Pich, A. (2024) · Nature Communications · doi:10.1038/s41467-024-52416-0 · Cited by 147
“Although collagen hydrolases are capable of degrading the basement membrane to release the trapped NCs 34,35 , this may also lead to irreversible destruction of basement membrane and increase the risk of cancer metastasis.”
Photo-triggered release of 5-fluorouracil from a MOF drug delivery vehicle
Stefaniak, K. R., Epley, C. C., Novak, J. J., McAndrew, M. L., Cornell, H. D., Zhu, J., McDaniel, D. K., Davis, J. L., Allen, I. C., Morris, A. J., et al. (2018) · Chemical Communications · doi:10.1039/c8cc01601a · Cited by 121
Perspectives of nanotechnology in male fertility and sperm function
Falchi, L., Khalil, W. A., Hassan, M. A. E., & Marei, W. F. A. (2018) · International Journal of Veterinary Science and Medicine · doi:10.1016/j.ijvsm.2018.09.001 · Cited by 121
“Major limitations for practical applications of NPs in vivo include overcoming the biological barriers to drug delivery, avoiding nonspecific distribution and targeting, as well as minimizing opsonization and clearance by the immune system after oral or intravenous administration [81].”
BackgroundSong, Y., Zhou, B., Du, X., Wang, Y., Zhang, J., Ai, Y., Xia, Z., & Zhao, G. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109561 · Cited by 124
Smart nanocarriers-based drug delivery for cancer therapy: An innovative and developing strategy
Huda, S., Alam, A., & Sharma, P. K. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102018 · Cited by 123
Liang, J., Li, X., Liu, H., Xia, J., Shi, X., & Shen, M. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101022 · Cited by 121
Microfluidic and Nanofluidic Intracellular Delivery
Hur, J., & Chung, A. J. (2021) · Advanced Science · doi:10.1002/advs.202004595 · Cited by 123
Mills, J. A., Liu, F., Jarrett, T. R., Fletcher, N. L., & Thurecht, K. J. (2022) · Biomaterials Science · doi:10.1039/d2bm00181k · Cited by 128
Polydopamine Nanoparticles for Combined Chemo- and Photothermal Cancer Therapy
Zhu, Z., & Su, M. (2017) · Nanomaterials · doi:10.3390/nano7070160 · Cited by 125
Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications
Gulati, N. M., Stewart, P. L., & Steinmetz, N. F. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00292 · Cited by 119
Fenaroli, F., Repnik, U., Xu, Y., Johann, K., Herck, S. V., Dey, P., Skjeldal, F. M., Frei, D. M., Bagherifam, S., Kocere, A., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b04433 · Cited by 121
A Smart Nanovector for Cancer Targeted Drug Delivery Based on Graphene Quantum Dots
Iannazzo, D., Pistone, A., Celesti, C., Triolo, C., Patanè, S., Giofrè, S. V., Romeo, R., Ziccarelli, I., Mancuso, R., Gabriele, B., et al. (2019) · Nanomaterials · doi:10.3390/nano9020282 · Cited by 121
Recent Advances in Magnetite Nanoparticle Functionalization for Nanomedicine
Popescu, R. C., Andronescu, E., & Vasile, B. Ş. (2019) · Nanomaterials · doi:10.3390/nano9121791 · Cited by 120
Nano–Bio Interactions: Biofilm‐Targeted Antibacterial Nanomaterials
Li, B., Mao, J., Wu, J., Mao, K., Jia, Y., Chen, F., & Liu, J. (2023) · Small · doi:10.1002/smll.202306135 · Cited by 123
Folate-mediated chemotherapy and diagnostics: An updated review and outlook
Xu, L., Bai, Q., Zhang, X., & Yang, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.02.023 · Cited by 119
“, nanoparticles of 50–100 nm tend to accumulate in the liver due to noncontinuous endothelia with vascular fenestrations; nanoparticles of 200–500 nm tend to accumulate in the spleen due to interendothelial cell slits; and microparticles of 2–5 μm tend to accumulate in the capillaries of the lungs [72].”
BackgroundExtracellular vesicle therapeutics for liver disease
Borrelli, D. A., Yankson, K., Shukla, N., Vilanilam, G. K., Ticer, T. D., & Wolfram, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.022 · Cited by 120
“In particular, systemically administered small molecules usually undergo rapid renal clearance, while nanoparticles preferentially accumulate in the liver [10,11].”
RGD engineered dendrimer nanotherapeutic as an emerging targeted approach in cancer therapy
Sheikh, A., Md, S., & Kesharwani, P. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.028 · Cited by 119
Advances and applications of nanoparticles in cancer therapy
Huang, X., He, T., Liang, X., Xiang, Z., Liu, C., Zhou, S., Luo, R., Bai, L., Kou, X., Li, X., et al. (2024) · MedComm – Oncology · doi:10.1002/mog2.67 · Cited by 130
Falvo, E., Tremante, E., Arcovito, A., Papi, M., Elad, N., Boffi, A., Morea, V., Conti, G., Toffoli, G., Fracasso, G., et al. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b01446 · Cited by 118
Kağa, S., Truong, N. P., Esser, L., Senyschyn, D., Sanyal, A., Sanyal, R., Quinn, J. F., Davis, T. P., Kaminskas, L. M., & Whittaker, M. R. (2017) · Biomacromolecules · doi:10.1021/acs.biomac.7b00995 · Cited by 118
Recent Advances in Managing Atherosclerosis via Nanomedicine
Chan, C. K. W., Zhang, L., Cheng, C. K., Yang, H., Huang, Y., Tian, X. Y., & Choi, C. H. J. (2017) · Small · doi:10.1002/smll.201702793 · Cited by 118
Feng, Q., Li, Y., Yang, X., Zhang, W., Hao, Y., Zhang, H., Hou, L., & Zhang, Z. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.011 · Cited by 118
“endow the formulation with excellent stability and dispersibility [30], with results showing that TPZ/HMTNPs-SNO dispersion in cell culture medium containing 10% fetal bovine serum remained always stable with minimal size changes over 24 h (Fig.”
BackgroundZheng, S., Wang, Y., Pan, S., Ma, E., Jin, S., Jiao, M., Wang, W., Li, J., Xu, K., & Wang, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100936 · Cited by 121
Wdowiak, M., Paczesny, J., & Raza, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091936 · Cited by 122
Programming Cell Adhesion for On-Chip Sequential Boolean Logic Functions
Qu, X., Wang, S., Ge, Z., Wang, J., Yao, G., Li, J., Zuo, X., Shi, J., Song, S., Wang, L., et al. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b04040 · Cited by 117
Li, B., Tang, J., Chen, W., Hao, G., Kurniawan, N. D., Gu, Z., & Xu, Z. P. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.05.055 · Cited by 118
Feng, C., Yuan, X., Chu, K., Zhang, H., Ji, W., & Rui, M. (2018) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.12.003 · Cited by 116
Satpathy, M., Wang, L., Zieliński, R., Qian, W., Wang, Y. A., Mohs, A. M., Kairdolf, B. A., Ji, X., Capala, J., Lipowska, M., et al. (2019) · Theranostics · doi:10.7150/thno.29964 · Cited by 117
“An advantage of nanoparticle-based drug carriers is the reduction of systemic toxicity since they are unable to pass through normal vessels to be delivered into normal tissues, with the exception of macrophages in the liver and spleen [35].”
BackgroundA Bismuth Metal–Organic Framework as a Contrast Agent for X-ray Computed Tomography
Robison, L., Zhang, L., Drout, R. J., Li, P., Haney, C. R., Brikha, A., Noh, H., Mehdi, B. L., Browning, N. D., Dravid, V. P., et al. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.8b00778 · Cited by 117
Polymersome-based protein drug delivery – quo vadis?
Gouveia, M. G., Wesseler, J. P., Ramaekers, J., Weder, C., Scholten, P. B. V., & Bruns, N. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00106c · Cited by 119
Li, Z., Zhu, Y., Zeng, H., Wang, C., Xu, C., Wang, H., Wang, H., Li, S., Chen, J., Xiao, C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37150-3 · Cited by 120
Bacterial therapies at the interface of synthetic biology and nanomedicine
Hahn, J., Ding, S., Im, J., Harimoto, T., Leong, K. W., & Danino, T. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00119-4 · Cited by 125
“The impact of these properties on nanoparticle delivery in vivo has been extensively studied 68–70 ; however, the effect of surface charge on bacteria in vivo has not yet been well investigated.”
Uptake of extracellular vesicles into immune cells is enhanced by the protein corona
Dietz, L., Oberländer, J., Mateos‐Maroto, A., Schunke, J., Fichter, M., Krämer‐Albers, E., Landfester, K., & Mailänder, V. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12399 · Cited by 116
“Therefore, modifications like attachment of polyethylene glycol (PEG) are used to prolong the liposomes’ blood circulation time (Blanco et al., 2015; Torchilin, 2005).”
MethodEffect of partial PEGylation on particle uptake by macrophages
Sanchez, L., Yi, Y., & Yu, Y. (2016) · Nanoscale · doi:10.1039/c6nr07353k · Cited by 120
Liu, W., Ruan, M., Wang, Y., Song, R., Ji, X., Xu, J., Dai, J., & Xue, W. (2018) · Small · doi:10.1002/smll.201801754 · Cited by 117
Nanomedicine to target multidrug resistant tumors
Lepeltier, É., Rijo, P. M., Rizzolio, F., Popovtzer, R., Petrikaitė, V., Assaraf, Y. G., & Passirani, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100704 · Cited by 116
Huang, X., Williams, J. Z., Chang, R., Li, Z., Burnett, C. E., Hernández-López, R. A., Setiady, I., Gai, E., Patterson, D. M., Yu, W., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-00813-z · Cited by 111
Chemodynamic nanomaterials for cancer theranostics
Xin, J., Deng, C., Aras, Ö., Zhou, M., Wu, C., & An, F. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00936-y · Cited by 125
Thiolated Nanoparticles for Biomedical Applications: Mimicking the Workhorses of Our Body
Hock, N., Racaniello, G. F., Aspinall, S. R., Denora, N., Khutoryanskiy, V. V., & Bernkop‐Schnürch, A. (2021) · Advanced Science · doi:10.1002/advs.202102451 · Cited by 118
He, W., Li, X., Morsch, M., Ismail, M., Liu, Y., Rehman, F. U., Zhang, D., Wang, Y., Zheng, M., Chung, R. S., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c00320 · Cited by 116
Electroporation for nanomedicine: a review
Kim, K.-S., & Lee, W. G. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb00038c · Cited by 114
Martinez, J. O., Molinaro, R., Hartman, K. A., Boada, C., Sukhovershin, R. A., Rosa, E. D., Kuri, D., Zhang, S., Evangelopoulos, M., Carter, A. M., et al. (2018) · Theranostics · doi:10.7150/thno.22078 · Cited by 116
“This evidence suggests that the presence of other ‘markers of self’ on the leukosome surface, such as CD47 [63, 64] and major histocompatibility complex class I [65], are fundamental for MPS avoidance [42].”
BackgroundInfluentialLuo, L., Iqbal, M. Z., Chuang, L. I. U., Xing, J., Akakuru, O. U., Fang, Q., Li, Z., Dai, Y., Li, A., Guan, Y., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119464 · Cited by 114
Jin, Z., Nguyen, K. T., Go, G., Kang, B., Min, H.-K., Kim, S., Kim, Y., Li, H., Kim, C., Lee, S., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b03051 · Cited by 114
Zhou, M., Xing, Y., Li, X., Du, X. C., Xu, T., & Zhang, X. (2020) · Small · doi:10.1002/smll.202003834 · Cited by 114
Zhang, F., Guo, Z., Li, Z., Luan, H., Yu, Y., Zhu, A. T., Ding, S., Gao, W., Fang, R. H., Zhang, L., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn6157 · Cited by 173
“Nevertheless, the systemic administration of nanoparticles faces challenges from various biological barriers, often leading to the inefficiency of conventional nanoformulations in accumulating at metastatic sites ( 7 – 9 ).”
BackgroundTargeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles
Ning, S.-T., Lee, S., Wei, M., Peng, C., Lin, S. Y.-F., Tsai, M.-H., Lee, P., Shih, Y., Lin, C., Luo, T., et al. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b04403 · Cited by 113
Nanoparticle Surface Functionality Dictates Cellular and Systemic Toxicity
Saei, A. A., Yazdani, M., Lohse, S. E., Bakhtiary, Z., Serpooshan, V., Ghavami, M., Asadian, M., Mashaghi, S., Dreaden, E. C., Mashaghi, A., et al. (2017) · Chemistry of Materials · doi:10.1021/acs.chemmater.7b01979 · Cited by 116
Fucoidan Prolongs the Circulation Time of Dextran-Coated Iron Oxide Nanoparticles
Abdollah, M. R. A., Carter, T. J., Jones, C. L., Kalber, T. L., Rajkumar, V. S., Tolner, B., Gruettner, C., Thin, M. Z., Torres, J. B., Ellis, M. J., et al. (2018) · ACS Nano · doi:10.1021/acsnano.7b06734 · Cited by 113
Singh, S. K., Lillard, J. W., & Singh, R. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.017 · Cited by 113
“A recent study has shown that positively charged NPs rapidly clear from circulation [21].”
BackgroundTargeted Theranostic Nanoparticles for Brain Tumor Treatment
Mendes, M., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040181 · Cited by 117
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Chen, Q., Sun, T., & Jiang, C. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00622-6 · Cited by 115
Design of Smart Size‐, Surface‐, and Shape‐Switching Nanoparticles to Improve Therapeutic Efficacy
Li, X., Montague, E. C., Pollinzi, A., Lofts, A., & Hoare, T. R. (2021) · Small · doi:10.1002/smll.202104632 · Cited by 115
Merging data curation and machine learning to improve nanomedicines
Chen, C., Yaari, Z. A., Apfelbaum, E., Grodzinski, P. A., Shamay, Y., & Heller, D. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114172 · Cited by 119
Regulating nanomedicines: challenges, opportunities, and the path forward
Mangla, B., Kumar, P., Javed, S., Pathan, T., Ahsan, W., & Aggarwal, G. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2533107 · Cited by 126
Biomimetic carriers mimicking leukocyte plasma membrane to increase tumor vasculature permeability
Palomba, R., Parodi, A., Evangelopoulos, M., Acciardo, S., Corbo, C., Rosa, E. D., Yazdi, I. K., Scaria, S., Molinaro, R., Furman, N. E. T., et al. (2016) · Scientific Reports · doi:10.1038/srep34422 · Cited by 112
Tuning the In Vivo Transport of Anticancer Drugs Using Renal‐Clearable Gold Nanoparticles
Peng, C., Xu, J., Yu, M., Ning, X., Huang, Y., Du, B., Hernandez, E., Kapur, P., Hsieh, J., & Zheng, J. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201903256 · Cited by 111
Sun, Y., Ma, W., Yang, Y., He, M., Li, A., Bai, L., Yu, B., & Yu, Z. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.04.005 · Cited by 115
Metadata
- Authors
- Blanco, E., Shen, H., & Ferrari, M.
- Affiliations
- Houston Methodist (US)
- Venue
- Nature Biotechnology
- Published
- 2015-09
- Volume
- 33
- Issue
- 9
- Pages
- 941-951
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- PMC
- PMC4978509
- OpenAlex
- W2143463421
- Cited by
- 7,002
- References
- 123
- Citations by year
- 2026: 729 · 2025: 685 · 2024: 772 · 2023: 712 · 2022: 739 · 2021: 713 · 2020: 736 · 2019: 652 · 2018: 611 · 2017: 436 · 2016: 198 · 2015: 15
- FWCI
- 150.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (U54CA151668, U54CA143837)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- nanoparticle drug delivery, nanocarrier design, biological barriers, local drug delivery, intravenous administration, tumor accumulation, cancer therapeutics, inflammation, nanotherapeutics
- MeSH terms
- Biocompatible Materials, Drug Compounding, Drug Design, Nanomedicine, Nanocapsules
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
